Check omega 3 claims before buying
Before paying for a supplement for your child's ADHD, talk through the evidence and the safety.
Low certaintyADHD evidence
Start with the time you have
1 minute
Write down exactly what improvement you'd expect before paying for an ADHD supplement.
5 minutes
List the supplements and medicines you want a pharmacist to review.
15 minutes
Read the Cochrane summary and prepare questions about likely benefit, cost and safety.
How sure the science is
Low certainty, ADHD evidence
The number could be quite different. Few trials, or trials with weak spots. Measured in people with ADHD.
- 15 trials
- 963 people
- children and teens
- parent rated
- 3 to 6 months
- measured on core ADHD symptoms
EBI-ADHD re-estimation: 15 trials, 963 young people, parent-rated core symptoms at medium-term follow-up. See this row on the evidence map
The number, drawn
Why it matters
EBI-ADHD found an almost zero estimated benefit from polyunsaturated fatty acids on parent-rated symptoms at about 26 weeks: SMD 0.049, with a 95% confidence interval from -0.101 to 0.198. Certainty was low, and the interval includes no benefit. The Cochrane review rated it high certainty that these supplements had no effect on parent-rated total symptoms in the medium term, SMD -0.08. So this evidence does not support promising that omega 3 supplements will improve your child's ADHD.
How to do it
- Ask which ADHD outcome the supplement claim rests on, and how certain the result is.
- Bring any supplements already used to a pharmacist or clinician review.
- Talk about nutrition separately from promises to treat ADHD.
Discuss supplements with a clinician or pharmacist, especially alongside medicines. This is an evidence review, not a recommendation to self-treat.
Putting it into practice
In real life
- Ask a pharmacist to review a supplement already in your child's cupboard.
- Compare an advert's promise with the review's finding that a meaningful symptom benefit is not established.
Watch out for
- Common mistakeA tiny average estimate is no guarantee of improvement. Check the uncertainty as well as the headline.
- Common mistakeSupplement safety depends on the whole medicine list, so include non-prescription products in a review.
Trusted guides
How we rated it
- Evidence grade
- B Trials in ADHD with low certainty, or strong general health evidence with a sourced reason it matters more with ADHD.
- The number
- Low certainty: omega 3 barely differs from placebo on symptoms at about 26 weeks (SMD 0.049) (Gosling et al., EBI-ADHD team (BMJ 2025 supplement), 2025)
- Benefit
- 32/100 The benefit score is an editorial prioritization for the general list, weighted by certainty. It is not a prediction of what will happen for you.
- Effort
- Some effort
Sources
- Tier 1 guidelineSupplementary materials for EBI-ADHDGosling et al., EBI-ADHD team (BMJ 2025 supplement), 2025
- Tier 1 guidelineBenefits and harms of ADHD interventions: umbrella review and platform for shared decision makingBMJ, 2025
- Tier 1 guidelinePolyunsaturated fatty acids (PUFA) supplements for attention deficit hyperactivity disorder (ADHD) in children and adolescentsCochrane, 2023
- Tier 1 guidelineMedication Safety and Your HealthCDC, 2024
General information about ADHD, not a diagnosis or an individual treatment plan. Tailoring changes the order of suggestions; it does not assess you. Medication decisions belong with you and a qualified clinician.